Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
21 shown of 6,799 total abstracts
  1. Abstract LBA4000LBA2026-06-05 · 19:00 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-286
    S. Tolaney, H. Rugo, S. Antonia · Dana-Farber Cancer Institute
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  2. Abstract LBA4001LBA2026-06-03 · 14:15 CT · E450
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-260 study)
    M. Reck, S. Tolaney · Chinese University of Hong Kong
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  3. Abstract LBA4002LBA2026-06-01 · 16:00 CT · S406
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    G. Curigliano, R. Herbst, L. Paz-Ares, et al. · Royal Marsden Hospital
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  4. Abstract LBA4003LBA2026-06-02 · 16:15 CT · Arie Crown Theater
    DESTINY-Breast-895: Enhertu (trastuzumab deruxtecan) 3L+ in HR+ breast cancer
    C. Saura, L. Paz-Ares, J. Cortes, et al. · Chinese University of Hong Kong
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  5. Abstract LBA4004LBA2026-06-03 · 21:30 CT · Hall B1
    Long-term follow-up of Trodelvy 2L for TNBC: ASCENT-835
    A. Spira, S. Antonia, P. Schmid, et al. · Peter MacCallum Cancer Centre
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  6. Abstract LBA4005LBA2026-06-05 · 18:00 CT · E450
    Lynparza plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from OlympiA-91
    N. Rizvi, L. Paz-Ares, H. Rugo · Institut Gustave Roussy
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  7. Abstract LBA4006LBA2026-06-04 · 18:15 CT · Arie Crown Theater
    MONARCH-996: Verzenio (abemaciclib) 1L in HR+ breast cancer
    S. Peters, C. Saura, H. Borghaei, et al. · Mayo Clinic
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  8. Abstract LBA4007LBA2026-06-04 · 13:30 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-172
    S. Modi, M. Krop, S. Tolaney, et al. · Stanford Cancer Institute
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  9. Abstract LBA4008LBA2026-06-03 · 18:15 CT · Arie Crown Theater
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    S. Tolaney, J. Cortes, E. Winer, et al. · Johns Hopkins Kimmel Cancer Center
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  10. Abstract LBA4009LBA2026-06-03 · 18:15 CT · E450
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-595 study)
    E. Winer, S. Peters, C. Robert, et al. · Massachusetts General Hospital
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  11. Abstract LBA4010LBA2026-06-01 · 16:15 CT · Hall B1
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    A. Spira, H. Rugo, N. Rizvi · Princess Margaret Cancer Centre
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  12. Abstract LBA4011LBA2026-06-01 · 15:30 CT · E450
    Long-term follow-up of Trodelvy maintenance for TNBC: ASCENT-971
    S. Antonia, S. Modi · Peter MacCallum Cancer Centre
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  13. Abstract LBA4012LBA2026-06-02 · 18:45 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-526 study)
    S. Tolaney, G. Curigliano · Royal Marsden Hospital
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  14. Abstract LBA4013LBA2026-06-02 · 13:45 CT · S100A
    Long-term follow-up of Kisqali 3L+ for HR+ breast cancer: MONALEESA-357
    J. Brahmer, S. Antonia · Karolinska Institute
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  15. Abstract LBA4014LBA2026-06-02 · 18:15 CT · S406
    MONARCH-630: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    E. Winer, C. Robert, M. Reck, et al. · Johns Hopkins Kimmel Cancer Center
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  16. Abstract LBA4015LBA2026-06-03 · 15:30 CT · E450
    Quality of life outcomes with Lynparza in patients with HR+ breast cancer
    S. Modi, M. Reck, H. Rugo, et al. · National Cancer Center Japan
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  17. Abstract LBA4016LBA2026-06-02 · 19:15 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-722 study)
    J. Cortes, H. Rugo, A. Spira, et al. · Mayo Clinic
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  18. Abstract LBA4017LBA2026-06-03 · 14:00 CT · S406
    Quality of life outcomes with Keytruda in patients with TNBC
    P. Schmid, S. Tolaney, S. Antonia, et al. · Royal Marsden Hospital
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  19. Abstract LBA4018LBA2026-06-03 · 19:15 CT · Arie Crown Theater
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-927
    T. Mok, S. Modi, M. Reck · Stanford Cancer Institute
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  20. Abstract LBA4019LBA2026-06-04 · 18:45 CT · Arie Crown Theater
    OlympiA-245: Lynparza (olaparib) 3L+ in HR+ breast cancer
    A. Spira, E. Winer · Stanford Cancer Institute
    Plenary SessionBreast Cancer—Metastatic📄🖼️
  21. Abstract LBA4020LBA2026-06-05 · 20:15 CT · Arie Crown Theater
    Quality of life outcomes with Trodelvy in patients with TNBC
    L. Paz-Ares, M.C. Garassino, G. Curigliano, et al. · Massachusetts General Hospital
    Plenary SessionBreast Cancer—Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.